Life-threatening blood coagulation in covid19 patients – Why?

Blood coagulation in Covid19 patients is shocking
Spread the love

Health care workers were shocked to see covid19 patients dying of severe blood clotting. Since the beginning, they were trying to reach the impetus behind this rare occurrence. Finally, the researchers have found out much about life-threatening blood coagulation in covid19 patients. The recent research aids in decreasing the fatality rate.

Why does blood coagulation in covid19 patients occur?

The imbalance between a glycoprotein and its regulator leads to elevated blood coagulation in covid19 patients. According to the Royal College of Surgeons researchers in Ireland, aka RCSI, the irregularities in the level of Von Willebrand Factor and its regulator ADAMTS13 cause blood coagulation in severe corona patients. This research was published in the ‘Journal of Thrombosis and Haemostasis.’ In the ICU of Beaumont Hospital, Dublin, the researchers examined the samples of severe covid patients.

Blood clotting
Blood clotting (License details: here)

Von Willebrand Factor also called VWF is a glycoprotein. It is responsible for the platelet adhesion at the site of injury. Therefore, it plays a key role in hemostasis (prevention of blood loss). In the above-mentioned research, the VWF level elevates in the blood. Thereby enabling the coagulation mechanism. On the contrary, there is a decrease in ADAMTS13, which works as an anticlotting factor.

The normal clotting mechanism showing the relationship of VWF and ADAMST113 factor.
The normal clotting mechanism showing the relationship of VWF and ADAMST113 factor. (License details: here)

The lead author of the research, Dr. Jamie O’Sullivan, said,

We looked at the markers in the blood of these patients and tried to understand what was underpinning the blood clotting,” “We observed elevated levels of the protein, VWF.”

Dr. O’Sullivan

Furthermore, O’Sullivan explained that the level of VWF was analyzed six times elevated than in ordinary people. Therefore, decreasing the levels can be therapeutic for the covid patients. On the other side, to promote hemostasis we can increase the reduced ADAMTS13 level. As, ADAMTS13 is an anticlotting factor hence, reduces clotting.

Benefits of research

There could be parallel treatment. The researchers further said that although they know the core now. But still, they need more details of the research to implement the findings therapeutically.  The Irish researcher also explained that this research would be beneficial. It aids those people who are out of resources for vaccination in the world.

Statistics showing the highest proportion of blood clotting in covid patients.
Statistics showing the highest proportion of blood clotting in covid patients.
(For License details: click here)


Also, read about coronavirus immunity here.

Read about the Indian Covid variant here.

Read about the blood coagulation issues in AstraZeneca vaccine here.

About the Author:

Mehrosh Ahmer

Former team member of NaeTaze.com
More about Mehrosh Ahmer...

Related Posts:

Leave a Reply

Your email address will not be published. Required fields are marked *

X